secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001104659-23-090888
Event type: leadership
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata appoints Dr. Deborah Birx as CEO, secures $25M credit from Innoviva
--------------------------------------------------------------------------

- Dr. Deborah L. Birx appointed CEO and Board member; former Innoviva Board member and world-renowned healthcare leader.
- New $25M credit agreement with Innoviva; existing convertible credit maturity extended to Jan 10, 2025.
- Q2 loss from operations $(9.6)M; cash $12.5M at June 30, 2023; 36.1M shares outstanding.
- Phase 2 inhaled AP-PA02 in NCFB enrolling; AP-SA02 bacteremia study advancing to Phase 2a in 3Q23.
- $16.3M total grant funding from DoD/MTEC for AP-SA02 program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465923090888/0001104659-23-090888-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465923090888/tm2323624d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-090888

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer